JP2020500152A5 - - Google Patents

Download PDF

Info

Publication number
JP2020500152A5
JP2020500152A5 JP2019517351A JP2019517351A JP2020500152A5 JP 2020500152 A5 JP2020500152 A5 JP 2020500152A5 JP 2019517351 A JP2019517351 A JP 2019517351A JP 2019517351 A JP2019517351 A JP 2019517351A JP 2020500152 A5 JP2020500152 A5 JP 2020500152A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
antibody
composition according
patient
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2019517351A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020500152A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/054217 external-priority patent/WO2018064436A1/en
Publication of JP2020500152A publication Critical patent/JP2020500152A/ja
Publication of JP2020500152A5 publication Critical patent/JP2020500152A5/ja
Priority to JP2022026794A priority Critical patent/JP2022071020A/ja
Priority to JP2024053862A priority patent/JP2024088688A/ja
Withdrawn legal-status Critical Current

Links

JP2019517351A 2016-09-30 2017-09-29 抗il23特異的抗体で乾癬を治療する安全かつ有効な方法 Withdrawn JP2020500152A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022026794A JP2022071020A (ja) 2016-09-30 2022-02-24 抗il23特異的抗体で乾癬を治療する安全かつ有効な方法
JP2024053862A JP2024088688A (ja) 2016-09-30 2024-03-28 抗il23特異的抗体で乾癬を治療する安全かつ有効な方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662402403P 2016-09-30 2016-09-30
US62/402,403 2016-09-30
US201762532068P 2017-07-13 2017-07-13
US62/532,068 2017-07-13
PCT/US2017/054217 WO2018064436A1 (en) 2016-09-30 2017-09-29 Safe and effective method of treating psoriasis with anti-il23 specific antibody

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022026794A Division JP2022071020A (ja) 2016-09-30 2022-02-24 抗il23特異的抗体で乾癬を治療する安全かつ有効な方法

Publications (2)

Publication Number Publication Date
JP2020500152A JP2020500152A (ja) 2020-01-09
JP2020500152A5 true JP2020500152A5 (enExample) 2020-11-12

Family

ID=61757820

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019517351A Withdrawn JP2020500152A (ja) 2016-09-30 2017-09-29 抗il23特異的抗体で乾癬を治療する安全かつ有効な方法
JP2022026794A Withdrawn JP2022071020A (ja) 2016-09-30 2022-02-24 抗il23特異的抗体で乾癬を治療する安全かつ有効な方法
JP2024053862A Pending JP2024088688A (ja) 2016-09-30 2024-03-28 抗il23特異的抗体で乾癬を治療する安全かつ有効な方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022026794A Withdrawn JP2022071020A (ja) 2016-09-30 2022-02-24 抗il23特異的抗体で乾癬を治療する安全かつ有効な方法
JP2024053862A Pending JP2024088688A (ja) 2016-09-30 2024-03-28 抗il23特異的抗体で乾癬を治療する安全かつ有効な方法

Country Status (12)

Country Link
US (3) US20180094052A1 (enExample)
EP (1) EP3519049B1 (enExample)
JP (3) JP2020500152A (enExample)
KR (2) KR20190059305A (enExample)
AU (2) AU2017336799B2 (enExample)
CA (1) CA3037961A1 (enExample)
FI (1) FI3519049T3 (enExample)
IL (3) IL316408A (enExample)
MA (1) MA46366B1 (enExample)
MX (1) MX2019003703A (enExample)
SM (1) SMT202500497T1 (enExample)
WO (1) WO2018064436A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190135910A1 (en) 2017-11-06 2019-05-09 Janssen Biotech, Inc. Safe and Effective Method of Treating Psoriatic Arthritis with Anti-IL23 Specific Antibody
US20190269757A1 (en) 2018-03-05 2019-09-05 Janssen Biotech, Inc. Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody
MA52590A (fr) * 2018-05-11 2021-03-17 Janssen Biotech Inc Méthodes de traitement de la dépression à l'aide d'anticorps il-23
EP3824295A4 (en) * 2018-07-18 2022-04-27 Janssen Biotech, Inc. PREDICTORS WITH DELAYED ACTION AFTER TREATMENT WITH ANTI-IL23 SPECIFIC ANTIBODIES
MA55149A (fr) * 2018-11-20 2021-09-29 Janssen Biotech Inc Procédé sûr et efficace de traitement du psoriasis avec un anticorps spécifique anti-il-23
CN115697410A (zh) * 2020-04-20 2023-02-03 艾德沙生物科技研究公司 用于治疗急性呼吸窘迫综合征的组合物和方法
KR20230006551A (ko) * 2020-05-05 2023-01-10 얀센 바이오테크 인코포레이티드 항-il23 특이적 항체로 크론병을 치료하는 방법
JP2023528265A (ja) 2020-05-21 2023-07-04 ヤンセン バイオテツク,インコーポレーテツド Il-23に対する抗体及びtnfアルファに対する抗体の組み合わせ療法を用いた炎症性腸疾患の治療方法
WO2022013745A1 (en) * 2020-07-13 2022-01-20 Janssen Biotech, Inc. Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody
AU2022233792A1 (en) * 2021-03-12 2023-10-26 Janssen Biotech, Inc. Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody
BR112023024064A2 (pt) 2021-05-20 2024-01-30 Janssen Biotech Inc Método de tratamento de doença inflamatória intestinal com uma terapia de combinação de anticorpos para il-23 e tnf-alfa
WO2023111981A1 (en) * 2021-12-17 2023-06-22 Janssen Biotech, Inc. Il-23 specific antibodies for the treatment of systemic sclerosis
WO2024228135A1 (en) 2023-05-03 2024-11-07 Janssen Biotech, Inc. Method of treating crohn's disease with a combination of antibodies to il-23 and tnf alpha
TW202448936A (zh) 2023-05-03 2024-12-16 美商健生生物科技公司 以針對IL-23及TNF α的抗體的組合來治療潰瘍性結腸炎之方法

Family Cites Families (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4309989A (en) 1976-02-09 1982-01-12 The Curators Of The University Of Missouri Topical application of medication by ultrasound with coupling agent
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
GB2097032B (en) 1981-04-22 1984-09-19 Teron International Urban Dev A combined ceiling air and services distribution system mechanical chasse and structural roof member
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US5149636A (en) 1982-03-15 1992-09-22 Trustees Of Columbia University In The City Of New York Method for introducing cloned, amplifiable genes into eucaryotic cells and for producing proteinaceous products
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4818542A (en) 1983-11-14 1989-04-04 The University Of Kentucky Research Foundation Porous microspheres for drug delivery and methods for making same
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US6492107B1 (en) 1986-11-20 2002-12-10 Stuart Kauffman Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
DE3546806C2 (enExample) 1985-03-30 1991-03-28 Marc Genf/Geneve Ch Ballivet
US4766067A (en) 1985-05-31 1988-08-23 President And Fellows Of Harvard College Gene amplification
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5576195A (en) 1985-11-01 1996-11-19 Xoma Corporation Vectors with pectate lyase signal sequence
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
DE3600905A1 (de) 1986-01-15 1987-07-16 Ant Nachrichtentech Verfahren zum dekodieren von binaersignalen sowie viterbi-dekoder und anwendungen
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4767402A (en) 1986-07-08 1988-08-30 Massachusetts Institute Of Technology Ultrasound enhancement of transdermal drug delivery
US4889818A (en) 1986-08-22 1989-12-26 Cetus Corporation Purified thermostable enzyme
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4921794A (en) 1987-01-14 1990-05-01 President And Fellows Of Harvard College T7 DNA polymerase
US4795699A (en) 1987-01-14 1989-01-03 President And Fellows Of Harvard College T7 DNA polymerase
EP0832981A1 (en) 1987-02-17 1998-04-01 Pharming B.V. DNA sequences to target proteins to the mammary gland for efficient secretion
DE3852304T3 (de) 1987-03-02 1999-07-01 Enzon Labs Inc., Piscataway, N.J. Organismus als Träger für "Single Chain Antibody Domain (SCAD)".
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
CA1341235C (en) 1987-07-24 2001-05-22 Randy R. Robinson Modular assembly of antibody genes, antibodies prepared thereby and use
US4939666A (en) 1987-09-02 1990-07-03 Genex Corporation Incremental macromolecule construction methods
WO1989006283A1 (en) 1988-01-11 1989-07-13 Ingene (International Genetic Engineering, Inc.) Novel plasmid vector with pectate lyase signal sequence
US6010902A (en) 1988-04-04 2000-01-04 Bristol-Meyers Squibb Company Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity
US4956288A (en) 1988-04-22 1990-09-11 Biogen, Inc. Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA
US5130238A (en) 1988-06-24 1992-07-14 Cangene Corporation Enhanced nucleic acid amplification process
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5142033A (en) 1988-09-23 1992-08-25 Hoffmann-La Roche Inc. Structure-independent DNA amplification by the polymerase chain reaction
US5066584A (en) 1988-09-23 1991-11-19 Cetus Corporation Methods for generating single stranded dna by the polymerase chain reaction
US5091310A (en) 1988-09-23 1992-02-25 Cetus Corporation Structure-independent dna amplification by the polymerase chain reaction
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US4987893A (en) 1988-10-12 1991-01-29 Rochal Industries, Inc. Conformable bandage and coating material
ATE102631T1 (de) 1988-11-11 1994-03-15 Medical Res Council Klonierung von immunglobulin sequenzen aus den variabelen domaenen.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US4994370A (en) 1989-01-03 1991-02-19 The United States Of America As Represented By The Department Of Health And Human Services DNA amplification technique
US5266491A (en) 1989-03-14 1993-11-30 Mochida Pharmaceutical Co., Ltd. DNA fragment and expression plasmid containing the DNA fragment
DE3909708A1 (de) 1989-03-23 1990-09-27 Boehringer Mannheim Gmbh Verfahren zur herstellung bispezifischer antikoerper
CA2016841C (en) 1989-05-16 1999-09-21 William D. Huse A method for producing polymers having a preselected activity
CA2016842A1 (en) 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
AU652539B2 (en) 1989-05-16 1994-09-01 Medical Research Council Co-expression of heteromeric receptors
DE69029036T2 (de) 1989-06-29 1997-05-22 Medarex Inc Bispezifische reagenzien für die aids-therapie
KR0185192B1 (ko) 1989-10-05 1999-04-01 제임스 더블유. 데이비 신규의 유전자 및 폴리펩티드의 무세포 합성 및 분리
US5139400A (en) 1989-10-11 1992-08-18 Ide Russell D Progressive cavity drive train
FR2656431B1 (fr) 1989-12-22 1994-06-10 Essilor Int Procede et solution pour decontaminer une lentille souple, en particulier du type hydrophile.
CA2050918A1 (en) 1990-01-12 1991-07-13 Raju Kucherlapati Generation of xenogeneic antibodies
TW212184B (enExample) 1990-04-02 1993-09-01 Takeda Pharm Industry Co Ltd
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
DE69128362T2 (de) 1990-06-01 1998-05-20 Chiron Corp Zusammensetzungen und verfahren zur identifizierung von molekülen mit biologischer wirksamkeit
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
KR0149181B1 (ko) 1990-06-29 1998-08-17 데이비드 알, 맥지 형질전환된 미생물에 의한 멜라닌의 제조방법
US5580734A (en) 1990-07-13 1996-12-03 Transkaryotic Therapies, Inc. Method of producing a physical map contigous DNA sequences
EP0542810A1 (en) 1990-08-02 1993-05-26 B.R. Centre Limited Methods for the production of proteins with a desired function
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1994025585A1 (en) 1993-04-26 1994-11-10 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
DE69133476T2 (de) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgene Mäuse fähig zur Produktion heterologer Antikörper
WO1992005258A1 (en) 1990-09-20 1992-04-02 La Trobe University Gene encoding barley enzyme
AU8727291A (en) 1990-10-29 1992-06-11 Cetus Oncology Corporation Bispecific antibodies, method of production, and uses thereof
EP0564531B1 (en) 1990-12-03 1998-03-25 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
US5582996A (en) 1990-12-04 1996-12-10 The Wistar Institute Of Anatomy & Biology Bifunctional antibodies and method of preparing same
JPH06508022A (ja) 1991-02-21 1994-09-14 ギリアド サイエンシズ,インコーポレイテッド 生体分子に特異的なアプタマーおよび生産方法
ATE240740T1 (de) 1991-03-15 2003-06-15 Amgen Inc Pegylation von polypeptiden
DK1471142T3 (da) 1991-04-10 2009-03-09 Scripps Research Inst Heterodimere receptor-biblioteker under anvendelse af fagemider
DE4118120A1 (de) 1991-06-03 1992-12-10 Behringwerke Ag Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5968502A (en) 1991-11-05 1999-10-19 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
ATE408012T1 (de) 1991-12-02 2008-09-15 Medical Res Council Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
CA2103887C (en) 1991-12-13 2005-08-30 Gary M. Studnicka Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
DE4207475A1 (de) 1992-03-10 1993-09-16 Goldwell Ag Mittel zum blondieren von menschlichen haaren und verfahren zu dessen herstellung
KR100323307B1 (ko) 1992-07-10 2002-11-30 바르네케호르스트 박판으로된강철제상자를제조하기위한생산라인
AU5322494A (en) 1992-10-02 1994-04-26 Trustees Of Dartmouth College Bispecific reagents for redirected targeting of low density lipoprotein
US5643252A (en) 1992-10-28 1997-07-01 Venisect, Inc. Laser perforator
WO1994012520A1 (en) 1992-11-20 1994-06-09 Enzon, Inc. Linker for linked fusion polypeptides
US5770428A (en) 1993-02-17 1998-06-23 Wisconsin Alumni Research Foundation Chimeric retrovial expression vectors and particles containing a simple retroviral long terminal repeat, BLV or HIV coding regions and cis-acting regulatory sequences, and an RNA translational enhancer with internal ribsome entry site
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
DE4337197C1 (de) 1993-10-30 1994-08-25 Biotest Pharma Gmbh Verfahren zur selektiven Herstellung von Hybridomazellinien, die monoklonale Antikörper mit hoher Zytotoxizität gegen humanes CD16-Antigen produzieren, sowie Herstellung bispezifischer monoklonaler Antikörper unter Verwendung derartiger monoklonaler Antikörper und des CD30-HRS-3-Antikörpers zur Therapie menschlicher Tumore
SE9304060D0 (sv) 1993-12-06 1993-12-06 Bioinvent Int Ab Sätt att selektera specifika bakteriofager
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
DK0749325T3 (da) 1994-03-07 2002-10-07 Medarex Inc Bispecifikke molekyler med klinisk anvendelse
US5763733A (en) 1994-10-13 1998-06-09 Enzon, Inc. Antigen-binding fusion proteins
US6294353B1 (en) 1994-10-20 2001-09-25 Morphosys Ag Targeted hetero-association of recombinant proteins to multi-functional complexes
GB9425232D0 (en) 1994-12-14 1995-02-08 Secr Defence Method of authenticating watermarked paper
US5549551A (en) 1994-12-22 1996-08-27 Advanced Cardiovascular Systems, Inc. Adjustable length balloon catheter
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6037453A (en) 1995-03-15 2000-03-14 Genentech, Inc. Immunoglobulin variants
US5656730A (en) 1995-04-07 1997-08-12 Enzon, Inc. Stabilized monomeric protein compositions
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
DE69621940T2 (de) 1995-08-18 2003-01-16 Morphosys Ag Protein-/(poly)peptidbibliotheken
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
DE19624387C2 (de) 1996-06-19 1999-08-19 Hatz Motoren Kaltstartvorrichtung
ATE210682T1 (de) 1996-09-03 2001-12-15 Gsf Forschungszentrum Umwelt Zerstörung von kontaminierenden tumorzellen in stammzelltransplantaten mit bispezifischen antikörpern
DK1500329T3 (da) 1996-12-03 2012-07-09 Amgen Fremont Inc Humane antistoffer, der specifikt binder TNF-alfa
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
IL120943A (en) 1997-05-29 2004-03-28 Univ Ben Gurion A system for administering drugs through the skin
JP4526702B2 (ja) 1997-09-29 2010-08-18 ネクター セラピューティックス 安定化生物活性処方物およびその使用方法
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
EP2364997A3 (en) 1999-01-15 2012-07-04 Genentech, Inc. Polypeptide variants with altered effector function
AU2002307037B2 (en) 2001-04-02 2008-08-07 Biogen Idec Inc. Recombinant antibodies coexpressed with GnTIII
KR20100018071A (ko) 2001-08-03 2010-02-16 글리카트 바이오테크놀로지 아게 항체 의존적 세포 독성이 증가된 항체 글리코실화 변이체
AU2003247411A1 (en) 2002-05-23 2003-12-12 Cognis Corporation NON-REVERTIBLE Beta-OXIDATION BLOCKED CANDIDA TROPICALIS
DK2548577T3 (en) * 2005-12-29 2017-03-13 Janssen Biotech Inc HUMAN ANTI-IL-23 ANTIBODIES, COMPOSITIONS, PROCEDURES AND APPLICATIONS
WO2009114040A2 (en) * 2007-09-28 2009-09-17 Centocor Ortho Biotech Inc. Anti-il-12/23p40 antibodies, epitopes, formulations, compositions, methods and uses
JP5155355B2 (ja) 2010-04-07 2013-03-06 レノボ・シンガポール・プライベート・リミテッド 無線基地局の自律的な負荷調整が可能な無線端末装置
US9803010B2 (en) * 2012-06-27 2017-10-31 Merck Sharp & Dohme Corp. Crystalline anti-human IL-23p19 antibodies
TWI503850B (zh) 2013-03-22 2015-10-11 Polytronics Technology Corp 過電流保護元件
MY186840A (en) * 2014-08-26 2021-08-25 Amgen K A Inc Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy
EP4670787A2 (en) * 2015-02-04 2025-12-31 Boehringer Ingelheim International GmbH METHODS OF TREATMENT FOR INFLAMMATORY DISEASES
US9816280B1 (en) 2016-11-02 2017-11-14 Matthew Reitnauer Portable floor
MA46861A (fr) * 2016-11-16 2019-09-25 Janssen Biotech Inc Procédé de traitement du psoriasis avec un anticorps anti-il-23 spécifique

Similar Documents

Publication Publication Date Title
JP2020500152A5 (enExample)
IL316408A (en) A safe and effective method for treating psoriasis with a specific anti-IL23 antibody
JP2020502261A5 (enExample)
JP2019531273A5 (enExample)
JP6554155B2 (ja) Il−17アンタゴニストを使用して汎発性膿疱性乾癬(gpp)を処置する方法
JP2021502349A5 (enExample)
WO2019096194A1 (zh) Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途
ES2992409T3 (es) Métodos de tratamiento de la psoriasis en placas de nueva aparición usando antagonistas de IL-17
JP2019514858A5 (enExample)
JP2019517549A5 (enExample)
IL310216A (en) Methods of treating crohn's disease with anti-il23 specific antibody
JP2018515493A5 (enExample)
BR112015006189A2 (pt) anticorpo anti-gm-csf, composição farmacêutica, e, uso de um anticorpo anti-gm-csf na fabricação de um medicamento
TW201204360A (en) Treatment of multiple sclerosis with MASITINIB
FI3359572T3 (fi) Menetelmä multippeliskleroosin hoitamiseksi
RU2019108441A (ru) Режим дозирования
JPWO2019171252A5 (enExample)
TW202308641A (zh) 用於治療癌症之方法及包含cdk抑制劑之給藥方案
JPWO2020012244A5 (enExample)
IL316022A (en) Method of treating mild to moderate psoriasis with il-23 specific antibody
JPWO2020016838A5 (enExample)
JPWO2021161270A5 (enExample)
IL312778A (en) Methods of treating crohn's disease with anti-il23 specific antibody
WO2025106815A1 (en) Combination of an fgfr4 inhibitor with a ppar agonist
JPWO2021224823A5 (enExample)